WHISTLE-PF: Study Design of a Phase 2b, Multi-center, Randomized, Double-blind, Controlled Trial of ENV-101 (Taladegib) in Patients With Idiopathic Pulmonary Fibrosis (ATS 2025) - Feb 24, 2025 - Pres time: May 18, 2025; 11:30 AM - 01:15 PM; Location: Area G; Poster Board # P863; P2 | "WHISTLE-PF will evaluate the dose-ranging effects of the novel Hhi ENV-101 in patients with IPF. The results will increase our understanding of the potential of Hh pathway inhibition as a therapeutic approach to IPF."
Clinical • P2b data • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
|
|
Jonathan G. Goldin, MD PhD; Jamielle Gibbs, MPH; Miguel De Los Rios, PhD; Philip L. Molyneaux, MD, PhD; Anita Difrancesco, BSc; Toby M. Maher, MD, MSc, PhD, FRCP; John Hood, PhD, BS; John C. Huetsch, MD
|